KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Raw Materials (2019 - 2025)

Opko Health (OPK) has disclosed Raw Materials for 4 consecutive years, with $11.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Raw Materials fell 25.56% year-over-year to $11.5 million, compared with a TTM value of $11.5 million through Dec 2025, down 25.56%, and an annual FY2025 reading of $11.5 million, down 25.56% over the prior year.
  • Raw Materials was $11.5 million for Q4 2025 at Opko Health, down from $12.0 million in the prior quarter.
  • Across five years, Raw Materials topped out at $29.3 million in Q2 2023 and bottomed at $6.8 million in Q4 2022.
  • Average Raw Materials over 4 years is $13.3 million, with a median of $11.2 million recorded in 2025.
  • The sharpest move saw Raw Materials skyrocketed 281.98% in 2023, then plummeted 68.39% in 2024.
  • Year by year, Raw Materials stood at $6.8 million in 2022, then surged by 281.98% to $25.9 million in 2023, then tumbled by 40.12% to $15.5 million in 2024, then dropped by 25.56% to $11.5 million in 2025.
  • Business Quant data shows Raw Materials for OPK at $11.5 million in Q4 2025, $12.0 million in Q3 2025, and $11.5 million in Q2 2025.